Latest News
Travere Therapeutics, Inc.
- With Results Imminent, What Could the Market Be Underestimating at Strong Buy-Rated MakeMyTrip, Brixmor Property Group, FirstCash, Enova, FirstService, Travere Therapeutics, TTM Technologies, CBRE, Cadence Design Systems and Comfort Systems U
- Travere Therapeutics (Nasdaq:TVTX) - Stock Analysis
- An officer proposes selling 243,735 shares at Travere Therapeutics (TVTX).
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Travere Therapeutics (TVTX) Could Be 28% Undervalued As FILSPARI Data And Patent Land
- Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
- Investigation launched into Travere Therapeutics officers for possible self-dealing harming shareholders
- Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
- Travere chief makes way for former Amicus CEO—Chutes & Ladders
- Travere CEO Eric Dube on deciding to leave; Roche tees up a board seat for ex-Takeda chief
- Travere at Stifel forum: FILSPARI growth offsets leadership shift
Headlines from the last 30 days, linking to the original publishers. See all market news →